Pulmo BioTech Inc.

Investor Relations:

 

Pulmo BioTech is a publicly listed company which trades on the OTC under the symbol PLMO.PK and on the Open Market in Frankfurt under the symbol PBO.F.

 

The Board of Directors of Pulmo BioTech Inc comprises:

 

 

Garry McCann, Director & CEO

 

Garry was previously the Managing Director of NE Technology Ltd, a global leader in the design and manufacture of radiation detection equipment. Garry has also been active in the fields of Linear Accelerators for cancer therapy, Radio-nuclides for medical imaging, LCDs and Electronic Systems. Garry has an MBA from Warwick University Business School and a BSc in Physics from the University of Surrey.

 

 

Rajiv Garg, Director & Chief Financial Officer

 

Rajiv has twenty five years of extensive experience in the investment banking and finance industry covering financial control, evaluation of businesses, regulatory liaison and development of macro/micro risk management systems.

 

Rajiv was educated at Westminster College in London, UK and the University of Delhi in India. He has an Honours Degree in Commerce and is a Member of the Institute of Chartered Accountants, a Member of the Securities and Futures Authority and a Member of the Global Association of Risk Professionals.

 

 

Peter Hirshfield, Company Secretary

 

Peter has over 39 years of experience as outside general counsel specializing in corporate, business and securities law. In September 2004 he founded Hirshfield Law, a New York City law firm that represents emerging companies and entrepreneurs in all stages of their business life, from formation and routine business matters, through regulatory compliance, capital raising, restructuring, joint ventures, and merger and acquisition transactions. Peter has represented participants in reverse merger transactions and currently represents several public companies and a number of private companies. Prior to founding Hirshfield Law, Peter gained broad experience as a partner in several prominent New York City law firms and as an associate at Cravath, Swaine & Moore. He received his BA majoring in history from Brandeis University, Waltham MA, and his JD degree from New York University Law School, where he was Article & Book Review Editor of the NYU Law Review and a John Norton Pomeroy Scholar. Peter was admitted to the California Bar, where he is currently on inactive status, and is an active member of the New York Bar.

 

 

John Wallwork, Non-exec Chairman

 

Professor John Wallwork (Bsc, MBChB, FRCS(E), FRCS, FRCP(E), FRCP(London), FMedSci, MA) is currently Professor of Cardiothoracic Surgery and Director of Research & Development at Papworth Hospital NHS Foundation Trust, Cambridge.  

 

Before being appointed as a Consultant at Papworth Hospital in 1981, he was Chief Resident at Stanford University Hospital in California for nearly 2 years, where he first became involved in heart and heart-lung transplantation and has played a major role in the development of heart-lung transplantation at Papworth Hospital.  

 

He performed Europe’s first successful heart-lung transplant in 1984 and, with Professor Sir Roy Calne, the world’s first heart-lung and liver transplant in 1986.  During this period he and his colleague, Professor Tim Higenbottam, were the first to introduce the use of long-term Prostacycline for Primary Pulmonary Hypertension.  

 

He was Director of the Transplant Service from 1989 to 2006, chaired the UK Transplant Cardiothoracic Advisory Group from 1994 to 2006 and was Medical Director of Papworth Hospital from 1997 to 2002.  On 1st October 2002 the University of Cambridge awarded him an honorary Chair in Cardiothoracic Surgery.

 

 

© 2011 Pulmo BioTech Incorporated